Madrigal Pharmaceuticals Executive and Leadership Team

William Sibold, the Chief Executive Officer at Madrigal Pharmaceuticals, directs the company's overall strategic vision and operational execution. Sibold guides the development and commercialization of therapeutic candidates targeting cardiovascular, metabolic, and liver diseases, ensuring alignment with the company's mission to address critical unmet medical needs. Overseeing all corporate functions, Sibold drives progress on the lead candidate, MGL-3196, a liver-directed thyroid hormone receptor agonist currently in Phase II clinical trials. This leadership role involves fostering innovation, managing investor relations, and securing the resources necessary for advancing the pipeline. By championing the company's scientific approach, William Sibold ensures Madrigal Pharmaceuticals remains at the forefront of biopharmaceutical innovation, focusing on delivering impactful treatments to patients worldwide.

Ronald Filippo, the Chief Information Officer at Madrigal Pharmaceuticals, architects and oversees the company's technology infrastructure and digital strategy. Filippo ensures robust, secure, and scalable IT systems that support the organization's research, development, and commercialization efforts for cardiovascular, metabolic, and liver disease therapeutics. This involves managing data integrity, cybersecurity protocols, and the implementation of advanced technological solutions to enhance operational efficiency. Filippo's responsibilities extend to leveraging data analytics for strategic decision-making, supporting the advancement of MGL-3196 and other pipeline candidates. By driving technological innovation, Ronald Filippo enables Madrigal Pharmaceuticals to accelerate drug discovery and development processes, ensuring seamless integration of information systems across all departments and facilitating effective collaboration.

Clint Wallace, the Executive Vice President & Chief Human Resources Officer at Madrigal Pharmaceuticals, shapes and executes the human capital strategy to support the company's growth and mission. Wallace cultivates a high-performance culture, driving talent acquisition, development, and retention initiatives critical for advancing therapeutic candidates in cardiovascular, metabolic, and liver diseases. This executive leadership role encompasses overseeing employee relations, compensation and benefits, and organizational design to foster an environment conducive to scientific innovation and operational excellence. Wallace ensures that Madrigal Pharmaceuticals attracts and retains top talent, including scientists and clinicians vital for the progression of MGL-3196 through clinical trials. By prioritizing people, Clint Wallace strengthens the organization's capacity to achieve its ambitious goals in biopharmaceutical development.

Joanne Jones, the Senior Executive Assistant To the Chief Human Resources Officer and CITO at Madrigal Pharmaceuticals, provides critical administrative and operational support to key executive functions. Jones manages complex scheduling, coordinates high-level meetings, and facilitates communication between the Chief Human Resources Officer, Chief Information Officer, and other senior leaders. This role is essential for ensuring the smooth operation of human resources and information technology departments, directly impacting the efficiency of talent management and technology infrastructure supporting the company's biopharmaceutical development. Jones's meticulous organization and proactive approach enable executives to focus on strategic priorities, including the advancement of therapeutic candidates for cardiovascular, metabolic, and liver diseases. By maintaining seamless administrative processes, Joanne Jones contributes to the overall effectiveness of Madrigal Pharmaceuticals' leadership team.

David Soergel, the Chief Medical Officer at Madrigal Pharmaceuticals, spearheads the clinical development strategy for the company's therapeutic candidates. Soergel directs all aspects of clinical trials, including study design, execution, and data analysis, focusing on treatments for cardiovascular, metabolic, and liver diseases. This leadership position is paramount to advancing MGL-3196, the company's lead candidate, through its Phase II trials for non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. Soergel ensures adherence to regulatory requirements and ethical standards, guiding the scientific evaluation of the drug's efficacy and safety. By overseeing the clinical research organization and medical affairs, David Soergel drives the scientific validation necessary for bringing innovative therapies to patients and solidifying Madrigal Pharmaceuticals' position in the biopharmaceutical sector.

Shannon Kelley, the Chief Legal Officer & Corporate Secretary at Madrigal Pharmaceuticals, provides comprehensive legal counsel and oversees corporate governance. Kelley manages all legal affairs, ensuring compliance with regulatory frameworks governing the pharmaceutical industry and protecting the company's intellectual property. This executive role is critical for navigating the complex legal landscape associated with drug development, including clinical trials and potential commercialization of therapeutic candidates for cardiovascular, metabolic, and liver diseases. Kelley advises the board of directors on legal and governance matters, ensuring robust corporate practices and risk mitigation strategies. By safeguarding the company's legal interests, Shannon Kelley supports the strategic objectives of Madrigal Pharmaceuticals, including the advancement of MGL-3196 and the overall integrity of its operations.